The intervention being tested is BNT323/DB-1303, an investigational drug administered via intravenous infusion. It is compared against standard chemotherapy options, doxorubicin or paclitaxel, chosen ...

The biotech company said Friday the latest version of its Covid-19 mRNA vaccine, Spikevax, has been authorized by Health Canada. And for the first time, all pre-filled syringe doses of the vaccine ...

New data from the Kentucky Cabinet for Health and Family Services shows cases of the virus have jumped significantly in the ...

BioNTech SE is currently sponsoring a Phase II clinical study titled A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

The top executives running the health care industry’s blue-chip companies amassed generational wealth in 2024, even as many ...

COVID-19 activity is rising in much of the country. Data shows overall respiratory virus spread is very low in the U.S. But ...

CureVac N.V., a biotech company developing medicines based on messenger RNA (mRNA), announced that CureVac N.V. and an affiliate of GSK plc have entered into agreements with BioNTech SE and affiliate ...

The Cancer Vaccine Launch Pad – a partnership between NHS England, the Government and BioNTech – has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers.

International, MNA | American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over ...